IL235927A - A drug that contains vascular disruption and causes oxygen deficiency to treat cancer - Google Patents
A drug that contains vascular disruption and causes oxygen deficiency to treat cancerInfo
- Publication number
- IL235927A IL235927A IL235927A IL23592714A IL235927A IL 235927 A IL235927 A IL 235927A IL 235927 A IL235927 A IL 235927A IL 23592714 A IL23592714 A IL 23592714A IL 235927 A IL235927 A IL 235927A
- Authority
- IL
- Israel
- Prior art keywords
- agent
- composition
- cancer treatment
- vascular disrupting
- targets hypoxia
- Prior art date
Links
- 206010021143 Hypoxia Diseases 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 239000003795 chemical substances by application Substances 0.000 title 1
- 230000007954 hypoxia Effects 0.000 title 1
- 239000004066 vascular targeting agent Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2012902291A AU2012902291A0 (en) | 2012-06-01 | Combination Therapy | |
| PCT/AU2013/000581 WO2013177633A1 (en) | 2012-06-01 | 2013-06-03 | Combination therapy involving a vascular disrupting agent and an agent which targets hypoxia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL235927A0 IL235927A0 (en) | 2015-01-29 |
| IL235927A true IL235927A (en) | 2017-11-30 |
Family
ID=49672192
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL235927A IL235927A (en) | 2012-06-01 | 2014-11-26 | A drug that contains vascular disruption and causes oxygen deficiency to treat cancer |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20150133401A1 (OSRAM) |
| EP (1) | EP2854796B1 (OSRAM) |
| JP (1) | JP6005855B2 (OSRAM) |
| CN (1) | CN104703595B (OSRAM) |
| AU (2) | AU2013204313C1 (OSRAM) |
| CA (1) | CA2874778A1 (OSRAM) |
| IL (1) | IL235927A (OSRAM) |
| NZ (1) | NZ630465A (OSRAM) |
| WO (1) | WO2013177633A1 (OSRAM) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107427487B (zh) * | 2015-03-05 | 2021-02-26 | 生态学有限公司 | 组合治疗方案 |
| KR102626155B1 (ko) | 2015-03-06 | 2024-01-17 | 비욘드스프링 파마수티컬스, 인코포레이티드. | Ras 돌연변이와 관련된 암의 치료 방법 |
| JP6904570B2 (ja) * | 2015-03-06 | 2021-07-21 | ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド | 脳腫瘍の治療方法 |
| AU2016291708B2 (en) | 2015-07-13 | 2020-12-24 | Beyondspring Pharmaceuticals, Inc | Plinabulin compositions |
| EP3413885A4 (en) | 2016-02-08 | 2019-09-18 | Beyondspring Pharmaceuticals, Inc. | COMPOSITIONS WITH TUCARESOL OR ITS ANALOG |
| SG11201810872UA (en) | 2016-06-06 | 2019-01-30 | Beyondspring Pharmaceuticals Inc | Composition and method for reducing neutropenia |
| US11633393B2 (en) | 2017-01-06 | 2023-04-25 | Beyondspring Pharmaceuticals, Inc. | Tubulin binding compounds and therapeutic use thereof |
| US11400086B2 (en) | 2017-02-01 | 2022-08-02 | Beyondspring Pharmaceuticals, Inc. | Method of reducing chemotherapy-induced neutropenia |
| WO2019055786A1 (en) * | 2017-09-14 | 2019-03-21 | Lankenau Institute For Medical Research | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER |
| JP7350015B2 (ja) | 2018-01-24 | 2023-09-25 | ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド | プリナブリンの投与による血小板減少症を軽減するための組成物および方法 |
| CN110680824A (zh) * | 2018-07-05 | 2020-01-14 | 深圳艾欣达伟医药科技有限公司 | 埃夫索胺的抗癌医药用途 |
| CN109675039A (zh) * | 2018-12-21 | 2019-04-26 | 中国科学院长春应用化学研究所 | 药物组合、抗肿瘤的药物和应用 |
| CN112755188B (zh) * | 2019-11-01 | 2022-03-08 | 中国科学院微生物研究所 | Shmt2抑制剂在制备抑制膀胱癌细胞生长和转移的药物中的应用 |
| WO2022216908A1 (en) | 2021-04-09 | 2022-10-13 | Beyondspring Pharmaceuticals, Inc. | Therapeutic compositions and methods for treating tumors |
| US20240366640A1 (en) | 2021-08-27 | 2024-11-07 | Ascentawits Pharmaceuticals, Ltd. | Lyophilized formulation solution and lyophilized formulation, and method and use thereof |
| WO2023025312A1 (zh) | 2021-08-27 | 2023-03-02 | 深圳艾欣达伟医药科技有限公司 | 使用th-302治疗parp抑制剂耐药的患者 |
| WO2023174319A1 (zh) | 2022-03-15 | 2023-09-21 | 深圳艾欣达伟医药科技有限公司 | 治疗brca突变癌症患者的方法 |
| CN119384281A (zh) | 2022-04-15 | 2025-01-28 | 深圳艾欣达伟医药科技有限公司 | 使用th-302单药或联用parp抑制剂治疗癌症的方法 |
| EP4529926A1 (en) | 2022-05-23 | 2025-04-02 | Ascentawits Pharmaceuticals, Ltd. | Method for treating cancer by combining alkylating agent prodrug and cell cycle inhibitor |
| WO2024061346A1 (zh) | 2022-09-22 | 2024-03-28 | 深圳艾欣达伟医药科技有限公司 | 乏氧激活的化合物在制备治疗癌症患者的药物中的用途 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5340062A (en) | 1992-08-13 | 1994-08-23 | Harmon Industries, Inc. | Train control system integrating dynamic and fixed data |
| US5886025A (en) | 1997-03-06 | 1999-03-23 | Baylor University | Anti-mitotic agents which inhibit tubulin polymerization |
| US6162930A (en) | 1998-03-06 | 2000-12-19 | Baylor University | Anti-mitotic agents which inhibit tubulin polymerization |
| US6849656B1 (en) | 1999-09-17 | 2005-02-01 | Baylor University | Indole-containing and combretastatin-related anti-mitotic and anti-tubulin polymerization agents |
| AUPR283801A0 (en) | 2001-02-01 | 2001-03-01 | Australian National University, The | Chemical compounds and methods |
| AU2003216322A1 (en) | 2002-02-15 | 2003-09-09 | Rigel Pharmaceuticals, Inc. | Inhibitors of tubulin polymerization |
| US7456214B2 (en) | 2004-05-03 | 2008-11-25 | Baylor University | Chromene-containing compounds with anti-tubulin and vascular targeting activity |
| CA2597447C (en) | 2005-02-14 | 2014-03-25 | Bionomics Limited | Novel tubulin polymerisation inhibitors |
| EP1896391B1 (en) | 2005-06-14 | 2015-08-12 | Baylor University | Combretastatin analogs with tubulin binding activity |
| CA2640678C (en) * | 2006-02-03 | 2015-03-31 | Bionomics Limited | Substituted benzofurans, benzothiophenes, benzoselenophenes and indoles and their use as tubulin polymerisation inhibitors |
| AU2007332143B2 (en) | 2006-12-11 | 2012-11-08 | Bionomics Limited | Chemical compounds and processes |
| WO2009126705A2 (en) * | 2008-04-10 | 2009-10-15 | Virginia Commonwealth University | Induction of tumor hypoxia for cancer therapy |
| CA2686587C (en) * | 2009-11-27 | 2018-01-16 | Bionomics Limited | Combination therapy for treating proliferative diseases |
| WO2011063469A1 (en) * | 2009-11-27 | 2011-06-03 | Bionomics Limited | Tubulin biomarker assay |
| US20110130367A1 (en) * | 2009-11-27 | 2011-06-02 | Bionomics Limited | Combination Therapy for Treating Proliferative Diseases |
| EP3311835B1 (en) * | 2010-07-12 | 2021-03-24 | Threshold Pharmaceuticals Inc. | Administration of hypoxia activated prodrugs and antiangiogenic agents for the treatment of cancer |
-
2013
- 2013-04-12 AU AU2013204313A patent/AU2013204313C1/en not_active Ceased
- 2013-06-03 WO PCT/AU2013/000581 patent/WO2013177633A1/en not_active Ceased
- 2013-06-03 NZ NZ630465A patent/NZ630465A/en not_active IP Right Cessation
- 2013-06-03 US US14/404,782 patent/US20150133401A1/en not_active Abandoned
- 2013-06-03 CN CN201380035499.3A patent/CN104703595B/zh not_active Expired - Fee Related
- 2013-06-03 EP EP13797528.0A patent/EP2854796B1/en not_active Not-in-force
- 2013-06-03 JP JP2015514291A patent/JP6005855B2/ja not_active Expired - Fee Related
- 2013-06-03 CA CA2874778A patent/CA2874778A1/en not_active Abandoned
- 2013-06-03 AU AU2013270425A patent/AU2013270425A1/en not_active Abandoned
-
2014
- 2014-11-26 IL IL235927A patent/IL235927A/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| NZ630465A (en) | 2015-09-25 |
| AU2013204313B2 (en) | 2015-09-03 |
| EP2854796A1 (en) | 2015-04-08 |
| CN104703595B (zh) | 2017-07-28 |
| EP2854796A4 (en) | 2015-10-14 |
| US20150133401A1 (en) | 2015-05-14 |
| HK1207286A1 (en) | 2016-01-29 |
| WO2013177633A1 (en) | 2013-12-05 |
| IL235927A0 (en) | 2015-01-29 |
| CN104703595A (zh) | 2015-06-10 |
| AU2013204313C1 (en) | 2016-04-07 |
| EP2854796B1 (en) | 2018-11-14 |
| CA2874778A1 (en) | 2013-12-05 |
| AU2013204313A1 (en) | 2013-12-19 |
| JP2015518008A (ja) | 2015-06-25 |
| AU2013270425A1 (en) | 2014-12-18 |
| JP6005855B2 (ja) | 2016-10-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL235927A (en) | A drug that contains vascular disruption and causes oxygen deficiency to treat cancer | |
| IL267242B (en) | Cancer treatment | |
| PL2740793T3 (pl) | Kompozycja leku do leczenia i/lub zapobiegania nowotworowi | |
| PL2818483T3 (pl) | Kompozycja lecznicza do leczenia i/lub zapobiegania nowotworowi | |
| PL2740795T3 (pl) | Kompozycja lekowa do leczenia nowotworu i/lub zapobiegania nowotworowi | |
| PL2740798T3 (pl) | Kompozycja leku do leczenia i/lub zapobiegania nowotworom | |
| PT2925888T (pt) | Composições e métodos para tratamento do cancro | |
| PL2818482T3 (pl) | Kompozycja farmaceutyczna do leczenia nowotworu | |
| PT2824114T (pt) | Composição farmacêutica para o tratamento do cancro | |
| PL2818481T3 (pl) | Kompozycja farmaceutyczna do leczenia i/lub zapobiegania nowotworowi złośliwemu | |
| PT3821830T (pt) | Dispositivo para tratar a oclusão vascular | |
| PL2532366T3 (pl) | Kompozycja farmaceutyczna do leczenia i/lub zapobiegania nowotworowi | |
| ZA201300692B (en) | Administration of hypoxia activated prodrugs and antiagiogenic agents for the treatment of cancer | |
| PL3967315T3 (pl) | Akkermansia muciniphila do leczenia nowotworu złośliwego | |
| HUE036424T2 (hu) | Gyógyászati készítmény májrák kezelésére és/vagy megelõzésére | |
| EP2825239A4 (en) | CATHETER HAVING ANTIMICROBIAL COATING | |
| IL238177A0 (en) | Methods and preparations for the treatment of cancer | |
| SG11201400976WA (en) | Methods and pharmaceutical compositions for treating cancer | |
| EP3020399A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF CANCER | |
| DK2872176T3 (en) | Cancer treatment | |
| EP2934500A4 (en) | COMBINATION THERAPY AGAINST CANCER | |
| PL2855475T3 (pl) | Alfa-karboliny do leczenia nowotworu | |
| SG11201509433RA (en) | Composition comprising a complex of (+)-catechin and amino acid for the treatment and prevention of cancer | |
| PL2663318T3 (pl) | Kompozycja farmaceutyczna do leczenia raka | |
| EP2887967A4 (en) | COMPOSITIONS AND METHODS FOR TREATING HEPATOCELLULAR CANCER |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed |